Shamburg News · 8-K filed Oct 14, 2026, 5:11 PM EDT
Rezolute Completes Enrollment in Phase 3 upLIFT Study of Ersodetug; Topline Data Expected Mid-December 2026
RZLT · Rezolute, Inc.
- Other event
- Reg FD disclosure
- Materiality: medium
Rezolute, Inc. announced on October 14, 2026 that the open-label Phase 3 upLIFT study of ersodetug in tumor hyperinsulinism is fully enrolled. The Company expects topline data in mid-December 2026 and plans to continue its expanded access program. The filing was furnished under Item 7.01 (Regulation FD) with the press release as Exhibit 99.1.
Source: SEC EDGAR, Form 8-K, Items 7.01, 9.01, accession 0001104659-26-115874.
Written from the filing by Shamburg Markets. Figures are as reported by the company.